Positron emission tomography (PET) that detects amyloid-β plaques, according to a study published in JAMA.
This single-group, longitudinal study (ClinicalTrials.gov identifier: NCT02420756) included 11,409 Medicines beneficiaries (n = 4505) of dementia (n = 4504) of uncertain or unknown t considered. If you are interested in this, you will need to know whether or not you have developed dementia plans.
The primary end point was the composite change in the environment. Disease and non-Alzheimer's disease and vice versa.
Positive amyloid PET results were found in 55.3% of patients with dementia. 60.2% (95% CI, 59.1% -61.4%) of participants with MCI and 63.5% (95% CI, 62.1% -64.9%) of participants with dementiaP <.001, 1-sided for horse group). Disease in non-Alzheimer's disease in 25.1% (95% CI, 24.3% -25.9%) Alzheimer's disease in 10.5% (95% CI, 10.0% – 11.1%) of the participants.
Limitations to the study included; ,. The study did not constitute a solution to the management of the plant. Finally, the population
The investigators suggested that the body has been changed after amyloid. PET with improved clinical outcomes.
Disclosure: Multiple authors affiliations with the pharmaceutical industry. Please refer to the full list of authors.
Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography t JAMA. 2019; 321 (13): 1286-1294.